Paloma Partners Management Company sold 72,500 shares as Pfizer Inc (Call) (PFE)'s stock declined 3.45%. Pfizer Inc now has $198.19 billion valuation. Overall, 12.79 Million shares exchanged hands versus its average trading volume of …
I have added to my taxable account 23.8994 shares at $33.39 for a total investment of $798.00 in Pfizer Inc. (NYSE:PFE). With this recent purchase, my taxable account holdings in PFE now totals 48.8994 shares with a market value of …
Stockman Wealth Management Inc. now owns 134,326 shares of the biopharmaceutical company's stock valued at $4,363,000 after buying an …
Baker Avenue Asset Management Lp acquired 30,977 shares as Pfizer Inc Com (PFE)'s stock declined 3.45%. It has underperformed by 16.70% the S&P500. Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, …
The stock rose 0.42% or $0.14 reaching $33.43 per share. The stock had a trading volume of 14,997,801 shares. (NYSE PFE) opened at 33.28 on Wednesday. It has underperformed by 19.46% the S&P500. Systematic Management Limited …
Shares of Pfizer Inc. (PFE) ended the trading day Wednesday at $33.36 ... 5.95 billion shares and on average sees 17 million shares exchange hands each day. The stock now has a 50-day SMA of $32.97 and 200-day SMA of $32.32, …
$38.57's average target is 15.38% above currents $33.43 stock price. (PFE) traded 27.26 million shares at hands. Stocks of Pfizer, (NYSE PFE) transacted up 0.63% on early Friday, topping $33.64. the share had a trading volume of …
Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company's stock worth $756,000 after buying an additional 84 shares during the period. About 2.88 million shares traded. (NYSE:PFE) has declined 2.76% …
Institutional investors and hedge funds own 70.10% of the company's stock. About 171,294 shares traded. (NYSE:PFE) has declined 2.76% since August 7, 2016 and is downtrending. It has outperformed by 14.45% the S&P500. Roof …
Pfizer Inc (NYSE:PFE) has potential upside of 11.4% based on a current price of $33.36 and analysts' consensus price target of $37.18. The stock should discover initial support at its 200-day moving average (MA) of $32.28 and subsequent …